Richard Marshak
Corporate Officer/Principal at TRISALUS LIFE SCIENCES, INC.
Net worth: 195 117 $ as of 2024-05-30
Richard Marshak active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Corporate Officer/Principal | 2023-08-09 | - |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Director/Board Member | 2018-08-31 | - |
| Founder | 2018-08-31 | - | |
| Corporate Officer/Principal | 2018-08-31 | - |
Career history of Richard Marshak
Former positions of Richard Marshak
| Companies | Position | Start | End |
|---|---|---|---|
LF Consulting
 LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | President | 2012-12-31 | 2022-05-31 |
Mount TAM Biotechnologies, Inc.
 Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Director/Board Member | 2016-02-29 | 2019-09-30 |
| Chief Executive Officer | 2016-02-29 | 2019-09-30 | |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 1998-12-31 | 2012-12-31 |
Training of Richard Marshak
| The University of Chicago Booth School of Business | Masters Business Admin |
| University of Pennsylvania | Undergraduate Degree |
Statistics
International
| United States | 7 |
| 2 |
Operational
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Private companies | 4 |
|---|---|
Mount TAM Biotechnologies, Inc.
Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Health Technology |
LF Consulting
LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Commercial Services |
| TriSalus Life Sciences, Inc. | |
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
- Stock Market
- Insiders
- Richard Marshak
- Experience
